Latest

Nvidia reportedly preparing to oust CEO Huang after alleged affairs with spy, Nvidia exec

Embattled Nvidia (NVDA) CEO Jensen Huang was allegedly involved in a second extramarital affair.

finance.yahoo.com 11-12-26

Gold Falls 1.6% as Hotter U.S. Inflation Data Pressures Rate-Cut Expectations Gold prices fell sharply, with December COMEX futures dropping

Gold prices fell sharply, with December COMEX futures dropping 1.62% to $3,935.50 per ounce, extending a five-day decline of roughly 4.3%. The latest selling...

11-12-26

EZCORP Jumps 11% After Hours as Record Revenue and Pawn Loan Growth Drive Strong Q4 EZCORP (NASDAQ: EZPW) shares surged

EZCORP (NASDAQ: EZPW) shares surged about 11% in after-hours trading after the pawn lender reported record fourth-quarter revenue, strong earnings growth and continued expansion...

11-12-26

Alvotech Rises 6.7% Premarket as Q3 Product Revenue Jumps and EBITDA More Than Doubles Alvotech (NASDAQ: ALVO) shares rose about

Alvotech (NASDAQ: ALVO) shares rose about 6.7% in premarket trading after the biosimilar drugmaker reported stronger third-quarter commercial performance, sharply higher adjusted EBITDA and...

11-12-26

Digi International Falls 15.6% After Hours as Fiscal 2027 Outlook Disappoints Despite Record Q4 Digi International (NASDAQ: DGII) shares fell

Digi International (NASDAQ: DGII) shares fell about 15.6% in after-hours trading despite record fourth-quarter revenue and strong earnings growth, as investors appeared to focus...

11-12-26

Teekay Tankers Edges 0.7% Higher After Hours as Record Q4 Spot Rates Point to Strong Finish Teekay Tankers (NYSE: TNK)

Teekay Tankers (NYSE: TNK) shares rose about 0.7% in after-hours trading after the company reported another strong quarter and said fourth-quarter spot tanker rates...

11-12-26

Okeanis Eco Tankers Falls 5.3% After Hours Despite Record Q3 Profit and $7 Dividend Okeanis Eco Tankers (NYSE: ECO) shares

(NYSE: ECO) shares fell about 5.3% in after-hours trading despite reporting a sharp increase in third-quarter revenue and profit, exceptionally strong...

11-12-26

EnerSys Falls 1.6% After Hours as Revenue Miss and Softer Q3 Outlook Offset Strong EPS Growth EnerSys (NYSE: ENS) shares

EnerSys (NYSE: ENS) shares fell about 1.6% in after-hours trading after the company reported strong earnings growth and margin expansion, but second-quarter revenue came...

11-12-26

Corteva Falls 8.5% After Hours as Brazil Weakness Drives Guidance Cut Corteva (NYSE: CTVA) shares fell about 8.5% in after-hours

Corteva (NYSE: CTVA) shares fell about 8.5% in after-hours trading after the company reported weaker third-quarter sales and earnings and lowered its full-year 2026...

11-12-26

CAE Edges 0.7% Higher After Hours as Company Raises Fiscal 2027 Earnings Outlook CAE (NYSE: CAE) shares rose about 0.7%

CAE (NYSE: CAE) shares rose about 0.7% in after-hours trading after the company raised its fiscal 2027 earnings and margin outlook, supported by stronger...

11-12-26

Tetra Tech Jumps 8.6% After Hours on Record Earnings and 13% Backlog Growth Tetra Tech (NASDAQ: TTEK) shares rose about

Tetra Tech (NASDAQ: TTEK) shares rose about 8.6% in after-hours trading after the engineering and consulting firm reported record quarterly and full-year earnings, margin...

11-12-26

Franco-Nevada Rises 4.2% After Hours as Higher Gold and Oil Prices Drive Q3 Earnings Growth Franco-Nevada (NYSE: FNV) shares rose

Franco-Nevada (NYSE: FNV) shares rose about 4.2% in after-hours trading after the company reported higher third-quarter revenue, cash flow and earnings, supported by stronger...

11-12-26

NASDAQ:NVDAFollow

Track all markets on TradingView - Prices are not updated in real time

Nvidia reportedly preparing to oust CEO Huang after alleged affairs with spy, Nvidia exec

Embattled Nvidia (NVDA) CEO Jensen Huang was allegedly involved in a second extramarital affair.

(finance.yahoo.com)

💬 🔗

European Investor 11-12-26

NVIDIA Expands Korea AI Strategy With Investments in Point2, Motif, RLWRLD and Upstage

NVIDIA announced new planned investments in Korean artificial intelligence startups, expanding its exposure across AI infrastructure, foundation models, enterprise software and robotics.

The company confirmed an investment in Point2 Technology and said additional investments are planned in Motif Technologies, RLWRLD and Upstage. The announcement came during the MSIT-NVIDIA AI Startup Partnership Forum in Seoul, hosted with Korea’s Ministry of Science and ICT.

Point2 develops radio-frequency interconnect technology designed to move data between chips and racks in AI factories, offering an alternative to conventional copper and optical connections. Motif Technologies develops foundation models for AI agents, while RLWRLD is building robotics foundation models for humanoid and industrial robots performing complex physical tasks.

Upstage focuses on enterprise AI, including its Solar language models and document AI tools for extracting information and automating business workflows.

The investments broaden NVIDIA’s engagement across the full AI stack, from data-center infrastructure to software and physical AI. They also deepen the company’s relationship with Korea’s technology ecosystem, where more than 1,000 startups already participate in the NVIDIA Inception program.

The initiative reinforces NVIDIA’s strategy of supporting companies that could expand demand for AI computing infrastructure while accelerating development of agentic AI, robotics and next-generation AI factories.

💬 🔗

The Investor 11-09-26

NVIDIA Says Vera CPU Delivers Faster AI Agent Performance With Higher Energy Efficiency

NVIDIA (NASDAQ: NVDA) said its Vera CPU can improve both AI agent performance and energy efficiency, targeting data centers increasingly constrained by power availability as agentic AI workloads expand.

According to NVIDIA, Vera enables 1.6 times more AI agents per watt than the fastest x86 CPU while delivering industry-leading agent speed. Compared with the most energy-efficient x86 processor tested, Vera delivered roughly twice the agent speed while maintaining strong power efficiency.

The company highlighted early performance results from several partners. Perplexity reported agentic coding workloads running 1.5 times faster on Vera than traditional CPUs, while DeepInfra achieved up to 2.2 times the speed of its best x86 processor in agent orchestration workloads.

Other tests showed ClickHouse scaling nearly linearly across 176 cores, while Daytona brought 1,000 AI-agent sandboxes online in 10.8 seconds compared with 88.4 seconds using x86 infrastructure. Modal reported up to twice the sandbox throughput per core.

The results reinforce NVIDIA’s push beyond GPUs into CPUs and full-stack AI infrastructure, as data center operators increasingly seek to maximize AI workloads per watt while supporting growing numbers of autonomous agents.

💬 🔗

Global Finance News 11-07-26

NVIDIA will host a conference call on Tuesday, November 17, at 5 p.m. ET to discuss its financial results for the third quarter of fiscal year 2027, which ended October 25, 2026.

💬 🔗

Global Finance News 11-01-26

NVIDIA Unveils Minerva AIOps Platform to Improve AI Factory Uptime and Yield

NVIDIA introduced Minerva, a new AIOps platform designed to give operators end-to-end observability across large-scale AI factories and help maximize GPU productivity.

Minerva combines telemetry from GPUs, networking, storage, schedulers and AI workloads into a unified operational view. NVIDIA said the platform builds a dynamic knowledge graph that maps infrastructure components such as GPUs, SuperNICs, switches and cables together with the workloads running across them.

The platform uses supervised and unsupervised machine learning to analyze billions of data points per hour, detect anomalies, predict emerging failures and correlate related events. Rather than surfacing every individual alert, Minerva is designed to group related symptoms into a smaller number of actionable incidents with likely root causes.

NVIDIA is positioning the platform around “AI factory yield,” which includes metrics such as GPU hours, goodput, cluster uptime and token production. The company said Minerva can help extend time between interruptions, reduce repair times and filter large volumes of telemetry into more meaningful operational signals.

Minerva also includes a native AI assistant and can connect with external agentic AI tools. This allows operators to investigate cluster health through natural-language queries and receive recommended remediation steps, while still keeping humans in the loop or connecting actions to automated infrastructure systems.

IREN is already using Minerva, while Aolani, Bitdeer AI, IBM, Jio, Lambda, Quake AI and Tesla plan to deploy the platform. Dell Technologies, Lenovo and Supermicro are also expected to offer Minerva as part of their AI factory operations portfolios.

The launch expands NVIDIA’s push beyond chips and systems into the software layer used to operate increasingly complex AI infrastructure, giving the company another way to deepen its role across the AI data-center stack.

💬 🔗

European Investor 10-22-26

NVIDIA Launches Isaac ROS 5.0 With Agentic AI Tools for Robotics Development

NVIDIA released Isaac ROS 5.0, expanding its open-source robotics platform with new agentic AI capabilities designed to help developers build, customize and deploy robotics applications faster.

The release adds support for ROS Lyrical and Ubuntu 24.04 while introducing reusable AI-agent skills for setup, manipulation and perception tasks. NVIDIA said new agent-ready documentation and workflows can help AI agents translate developer intent into working robotics applications more efficiently.

One of the key upgrades is FoundationPose, which now includes an agent-ready inference library that can track object position and orientation up to 5.5 times faster. NVIDIA also added a standalone pick-and-place skill combining detection, depth estimation and pose output for robotics developers.

The broader ecosystem is also expanding. RealSense, Intrinsic, Magna, Flexiv, Universal Robots, Mentee Robotics and others are using Isaac ROS across applications ranging from industrial automation and machine tending to humanoid robotics and autonomous manipulation.

Isaac ROS 5.0 supports hardware ranging from Jetson Orin Nano to Jetson Thor, allowing developers to move from development to on-device deployment as robotics workloads grow more complex. The software is available now as a free and open-source release.

💬 🔗

Global Finance News 09-22-26

NVIDIA Launches DSX Ready Program for AI Factory Power and Cooling Systems

NVIDIA introduced DSX Ready, a new qualification program designed to help AI factory builders identify power, cooling and infrastructure products that meet applicable NVIDIA DSX reference-design requirements.

The program launches with two initial categories: battery energy storage systems and cooling distribution units. Qualified BESS products include solutions from Hitachi Energy, LG Energy Solution and Tesla, while qualified CDU providers include LG Electronics, LiquidStack and Vertiv.

DSX Ready is intended to reduce integration risk as AI data centers face increasingly tight power, cooling, water and grid constraints. NVIDIA said the broader DSX platform is designed to treat compute, networking, power, cooling, facilities and software as a single coordinated system rather than separate infrastructure layers.

For battery systems, suppliers complete qualification testing and submit supporting data for NVIDIA review. Cooling providers use a self-qualification suite to determine whether specific CDU products meet NVIDIA’s functional requirements. The company emphasized that qualification does not replace site-level engineering.

NVIDIA plans to add more infrastructure and software categories over time. The initiative reflects the growing importance of power delivery and liquid cooling as AI factories scale to support increasingly dense computing systems.

💬 🔗

European Investor 09-21-26

NVIDIA, Google and Emerald AI Launch Alliance to Tackle AI Data Center Power Constraints

NVIDIA, Google and Emerald AI have launched the AI Energy Management Alliance, a new coalition aimed at making large AI data centers more flexible in how they consume electricity and accelerating their connection to power grids.

Power availability has become a major constraint on the expansion of U.S. AI infrastructure. The alliance is developing a framework that would allow AI data centers to adjust electricity consumption according to grid conditions by shifting computing workloads, using energy storage or paired generation, and reducing demand during periods of system stress.

The approach could allow utilities to connect large AI facilities more quickly while reducing the need for costly grid upgrades. AEMA plans to establish standardized performance requirements covering response times, power curtailment, emergency operations and data sharing between data centers and grid operators.

The initiative brings together AI companies, data center operators, power producers, utilities and grid operators. For NVIDIA and the broader AI industry, addressing electricity constraints is becoming increasingly important as rapidly expanding AI computing capacity requires substantially more power infrastructure.

💬 🔗

WS Investor 09-16-26

NVIDIA Brings Perplexity’s Local AI Agent to Windows RTX PCs

NVIDIA said Perplexity Portable Computer is now available on compatible Windows PCs powered by GeForce RTX and RTX PRO GPUs, expanding access to AI agents that can perform complex tasks locally rather than relying entirely on cloud computing.

Portable Computer is a local version of Perplexity Computer designed to plan and execute multistep tasks. NVIDIA GPUs accelerate local models that can analyze data, work across files and handle recurring tasks while keeping sensitive information on the device. Tasks completed locally also do not consume Perplexity Computer cloud credits.

The platform combines local and cloud AI. For more demanding reasoning tasks, the agent can determine that cloud processing is needed and ask for permission before sending information off-device. It can also connect with services including Microsoft Outlook, OneDrive, Word, Google Drive, Gmail, Slack and GitHub.

The development highlights NVIDIA’s push to expand AI computing beyond data centers and into personal computers. Running increasingly capable AI agents directly on RTX hardware could create another source of demand for high-memory GPUs as agentic AI becomes more integrated into everyday professional workflows.

Portable Computer requires a GeForce RTX or RTX PRO GPU with at least 24GB of VRAM, while support for NVIDIA DGX Station is expected later.

💬 🔗

WS Investor 09-14-26

NVIDIA Says Its AI Platform Is Powering the Global Robotaxi Expansion

NVIDIA is expanding its role in autonomous transportation as robotaxi developers, mobility platforms and automakers increasingly adopt the company’s computing technologies to train, simulate and operate driverless vehicles. NVIDIA says every major robotaxi program currently operating at commercial scale uses at least part of its modular technology stack.

The platform combines three major computing layers: NVIDIA DGX systems for AI model training, Omniverse and Cosmos running on RTX PRO servers for simulation and validation, and DRIVE Hyperion with DRIVE AGX Thor for in-vehicle computing. DRIVE Hyperion 10 uses dual Blackwell-based DRIVE AGX Thor chips alongside cameras, radar, lidar and ultrasonic sensors to provide 360-degree perception and redundant computing.

NVIDIA’s ecosystem now spans many of the biggest names in autonomous mobility. Uber plans to scale NVIDIA DRIVE Hyperion-based robotaxis to 28 cities by 2028 and is working with companies including Lucid, Mercedes-Benz, Nuro, Pony*ai, Wayve and WeRide. Lyft, Bolt, May Mobility and Waymo are also using or working with NVIDIA technologies.

Automakers including Mercedes-Benz, Stellantis, Hyundai, Kia, Geely and Zeekr are also integrating NVIDIA technology into autonomous-driving programs, while Tesla uses NVIDIA supercomputers to train its autonomous-driving neural networks.

The expansion positions NVIDIA to capture computing demand beyond data centers as physical AI moves toward commercial deployment in transportation.

💬 🔗

Global Finance News 09-11-26

Load More

11-12-26European Investor

11-11-26The Investor

11-11-26The Investor

11-10-26European Investor

11-09-26WS News

UKFollow

Track all markets on TradingView - Prices are not updated in real time

UK Manufacturing Rebounds in September While Business Investment Slows

UK manufacturing production rose 0.7% month over month in September, beating expectations for a 0.5% decline and matching the previous month’s 0.7% increase.

Industrial production increased 0.3% in September, also outperforming the forecast for a 0.4% contraction, though slowing from the prior 0.7% gain.

Business investment grew 0.4% quarter over quarter in the third quarter, in line with expectations but sharply below the 1.8% increase recorded in the previous quarter.

The data point to stronger-than-expected industrial activity at the end of the third quarter, while the slowdown in business investment suggests a more cautious corporate spending backdrop.

💬 🔗

European Investor 11-12-26

UK Economy Grows 0.7% in Q3 as September GDP Rises 0.2%

The UK economy expanded 0.7% quarter over quarter in the third quarter, matching expectations and accelerating from 0.5% growth in the previous quarter.

On an annual basis, GDP increased 1.9% in Q3, also in line with forecasts and up from 1.4% previously.

Monthly GDP rose 0.2% in September, outperforming expectations for no growth and improving from a flat reading in the previous month.

The data point to firmer economic momentum heading into the fourth quarter, with both quarterly and annual growth accelerating and September activity exceeding expectations.

💬 🔗

European Investor 11-12-26

UK Retail Sales Growth Edges Up to 1.1% in October

UK retail sales growth improved slightly in October, with the BRC Retail Sales Monitor rising 1.1% year over year.

The reading came in just below the 1.2% forecast but was stronger than the 1.0% increase recorded previously.

💬 🔗

European Investor 11-10-26

UK House Prices Fall 0.6% in October, Missing Expectations

UK house prices fell 0.6% month over month in October, significantly weaker than expectations for no change and following a 0.1% decline previously.

On an annual basis, house prices declined 1.2%, compared with the 0.3% contraction forecast and the previous 0.1% decline.

The sharper-than-expected deterioration points to renewed weakness in the UK housing market, suggesting affordability pressures and borrowing costs continue to weigh on demand.

💬 🔗

European Investor 11-06-26

Bank of England Holds Rates at 4.00%, Matching Forecast

The Bank of England kept its benchmark interest rate unchanged at 4.00% in November, in line with market expectations.

The decision follows the previous 3.75% rate and therefore represents a 25-basis-point increase from the prior level.

💬 🔗

The Investor 11-05-26

UK Labor Market Strengthens as Employment Jumps and Unemployment Falls

The U.K. labor market showed stronger-than-expected momentum in August, with employment rising sharply and the unemployment rate declining.

Employment increased by 102,000 on a three-month-on-three-month basis, far above the 20,000 consensus estimate and up from the previous increase of 67,000.

The unemployment rate fell to 4.7%, better than the 4.9% forecast and down from 4.9% previously.

The data point to a firmer labor market than economists expected, with stronger hiring and lower unemployment.

💬 🔗

WS News 10-20-26

UK Economy Grows 0.1% in August as Manufacturing and Industrial Output Beat Expectations

The U.K. economy expanded 0.1% month over month in August, outperforming expectations for a 0.1% contraction, although growth slowed from the previous month’s 0.4% increase.

Manufacturing production rose 1.2% month over month, significantly stronger than the 0.1% decline expected by economists and slightly above the previous month’s 1.0% gain.

Industrial production also surprised to the upside, increasing 0.8% versus expectations for a 0.1% decline and accelerating from 0.3% previously.

The trade deficit narrowed to £18.01 billion, better than the £21.90 billion deficit expected and an improvement from the previous reading shown in the data.

Overall, the figures point to more resilient U.K. economic activity than expected, particularly in manufacturing and industrial production.

💬 🔗

WS News 10-15-26

UK Retail Sales Growth Accelerates to 1.0% in September

UK retail sales increased 1.0% year over year in September, according to the BRC Retail Sales Monitor, exceeding expectations for a 0.8% gain and improving from 0.5% growth in the previous month.

The stronger reading suggests consumer spending gained momentum during September despite continued pressure from elevated borrowing costs and broader cost-of-living concerns.

💬 🔗

The Investor 10-13-26

UK House Prices Stabilize in September as Mortgage Rate Holds at 6.58%

UK house prices were unchanged month over month in September, matching market expectations and improving from a 0.3% decline in August.

On an annual basis, the Lloyds House Price Index was also flat at 0.0%, compared with a 0.4% decline in the previous month. The figures suggest the housing market stabilized in September after recent weakness.

Separately, the average UK mortgage rate remained unchanged at 6.58% in September.

The combination of stable house prices and unchanged mortgage costs points to a relatively steady housing backdrop, although elevated borrowing rates continue to constrain affordability and demand.

💬 🔗

European Investor 10-07-26

The UK S&P Global Construction PMI rose to 46.1 in September from 44.3 in August, beating expectations for a reading of 45.0.

Despite the improvement, the index remained below the 50 threshold that separates expansion from contraction, indicating that construction activity continued to decline during the month.

The stronger-than-expected reading suggests the pace of contraction eased in September, offering a modestly more positive signal for the UK construction sector.

💬 🔗

Global Finance News 10-06-26

Load More

09-17-26The Investor

08-29-26WS Investor

08-17-26WS Investor

06-22-26WS Investor

04-30-26Global Finance News

NASDAQ:CRWVFollow

Track all markets on TradingView - Prices are not updated in real time

CoreWeave Jumps 18% After Hours as Revenue Surges and 2026 Guidance Rises

CoreWeave (NASDAQ: CRWV) shares surged about 18% in after-hours trading after the AI cloud infrastructure provider reported a sharp acceleration in third-quarter revenue, expanding margins and higher full-year guidance.

Third-quarter revenue reached $3.66 billion, up from $1.37 billion a year earlier and more than $1 billion higher sequentially. Adjusted EBITDA rose to $2.26 billion, representing a 62% margin, while adjusted operating income reached $379 million and adjusted operating margin improved to 10%.

The company remained deeply loss-making on a GAAP basis, however. Net loss widened to $709 million from $110 million a year earlier, largely reflecting heavy financing costs. Net interest expense reached $846 million, while adjusted net loss was $529 million.

Demand visibility strengthened significantly, with revenue backlog reaching approximately $132.5 billion at the end of September. CoreWeave also expanded active power capacity to more than 1.7 GW and contracted power to more than 4.6 GW as it continued building out AI infrastructure globally.

Management raised full-year 2026 revenue guidance to $13.0-$13.3 billion and increased adjusted operating income guidance to $1.275-$1.375 billion, representing a 26% increase at the midpoint from its prior outlook. The company also lifted its year-end annualized run-rate revenue target to $20-$21 billion.

Capital spending remains extremely high, with CoreWeave now expecting 2026 capex of $37-$39 billion, while fourth-quarter interest expense is projected at $1.05-$1.15 billion.

The 18% after-hours rally appears to reflect the combination of accelerating revenue growth, a massive backlog, earlier-than-expected margin expansion and higher full-year guidance, outweighing continued concerns around leverage, interest expense and capital intensity.

💬 🔗

Global Finance News 11-11-26

CoreWeave Gains as JPMorgan Upgrades CRWV to Overweight, Raises Target to $125

CoreWeave (NASDAQ: CRWV) shares rose about 4% Thursday after JPMorgan upgraded the AI infrastructure company to Overweight from Neutral and raised its December 2027 price target to $125 from $120.

Analyst Samik Chatterjee cited strong demand for AI compute capacity, a favorable pricing environment and CoreWeave’s ability to secure short-term contracts at premium rates. Recent contracts have included terms of roughly three to six months, while higher compute pricing appears to be more than offsetting increased costs and supporting stronger contribution margins on new agreements. JPMorgan also pointed to pricing increases across the GPU compute market as evidence that demand remains tight (Blockspace).

The upgrade comes as CoreWeave continues to expand rapidly. Second-quarter revenue reached $2.58 billion, up 112% year over year, while backlog stood near $104 billion before including more than $25 billion of additional customer commitments secured early in the third quarter.

CoreWeave shares were trading around $90.29, up roughly 3.9%. JPMorgan’s new $125 target reflects expectations that strong AI infrastructure demand and improved pricing could continue to support revenue growth and margins.

💬 🔗

WS Investor 09-24-26

Load More

11-11-26The Investor

11-11-26Global Finance News

10-19-26WS News

09-12-26European Investor

NASDAQ:RUMFollow

Track all markets on TradingView - Prices are not updated in real time

RUM Group Jumps 14% as AI Infrastructure Drives Record Revenue and First Positive Adjusted EBITDA Quarter

RUM Group (NASDAQ: RUM) shares surged about 14% after the company reported record third-quarter revenue, strong GPU utilization and its first profitable quarter on an adjusted EBITDA basis.

Third-quarter revenue jumped 290% year over year to $96.6 million, also rising 139% sequentially and coming in 3.8% above the top end of company guidance. Quake AI contributed $68.2 million, representing more than 70% of total revenue in its first full quarter of consolidated results.

Demand for the company’s AI infrastructure remained strong. Quake AI operated approximately 22,000 NVIDIA GPUs at roughly 85% utilization during the quarter, with management describing the fleet as nearly sold out.

The quarter also marked RUM Group’s first positive adjusted EBITDA result, an important profitability milestone as the company shifts more heavily toward AI infrastructure. Rumble’s core business also recorded higher advertising revenue, although subscription and other services revenue declined.

RUM Group ended September with $142.3 million of liquidity, including $134.4 million in cash and cash equivalents and 94.68 Bitcoin valued at $7.9 million.

The company also increased its ownership of Northern Data to approximately 98% and expects to reach full ownership through a squeeze-out process in early 2027. However, management cautioned that part of its previously targeted 250 MW of unmonetized capacity for 2027 could be delayed beyond next year because of market conditions.

For the fourth quarter, RUM Group expects revenue of $88 million to $94 million, below the Q3 level.

The 14% rally appears to reflect the much stronger-than-expected revenue growth, high GPU utilization and first positive adjusted EBITDA quarter, which outweighed the softer sequential Q4 revenue outlook and potential delays to additional capacity deployment.

💬 🔗

The Investor 11-11-26

Rumble Slips 6% in Premarket as Thin Revenue and Northern Data Dilution Concern Investors

May 14, 2026 | NASDAQ: RUM

Rumble is under pressure in premarket despite reporting record first-quarter revenue, as the market focuses on the persistent gap between the platform's ambitions and its financial reality, compounded by the dilutive mechanics of the pending Northern Data acquisition.

Revenue grew 7% year-on-year to $25.5 million — a record for any first quarter — but the absolute number remains tiny for a company with significant infrastructure costs. Cost of services alone was $27 million, meaning Rumble is still generating negative gross profit on its core platform operations. G&A expenses fell 37% to $10.4 million as headcount rationalization took effect, which is a genuine positive, but sales and marketing jumped 134% to $8.5 million as the company invests to grow its user base. Total operating expenses of $51.7 million against $25.5 million in revenue means the cash burn remains substantial — the company ended Q1 with $233.4 million in liquidity, including 210.82 Bitcoin valued at $14.4 million.

MAUs reached 56 million, up 8% sequentially, driven by Rumble Shorts and international expansion — encouraging momentum that management will need to monetize more effectively over time. The Rumble Wallet launch in partnership with Tether, exclusive streaming rights to The Dan Bongino Show, and the new CFO appointment from Intel's VP of Product Management are all strategic moves but near-term revenue neutral.

The Northern Data acquisition is likely the primary driver of today's 5% decline. Rumble has secured approximately 81.3% of Northern Data shares through its exchange offer, with closing expected in mid-June at a ratio of 2.0281 new Rumble shares per Northern Data share — a meaningful dilution event for existing shareholders. Northern Data's Q1 revenue of EUR 43 million with GPU utilization reaching 85% in March is operationally encouraging and would bring pro forma combined revenue to approximately $75 million — nearly triple Rumble's standalone figure. But investors are weighing whether the AI cloud infrastructure pivot is the right use of Rumble's capital and shareholder equity.

The 5% drop reflects a market that sees a money-losing video platform taking on a leveraged AI infrastructure business through a dilutive share exchange, while still searching for a clear path to profitability on either front.

💬 🔗

Global Finance News 05-15-26

Load More

11-11-25The Investor

10-03-25The Investor

NYSE:SFFollow

Track all markets on TradingView - Prices are not updated in real time

Stifel Partners With Anthropic to Bring Claude AI Into Advisor Dashboard Platform

Stifel Financial (NYSE: SF) is working with Anthropic to modernize its Dashboard platform by integrating Claude-based artificial intelligence tools into the technology used by the firm’s financial advisors.

The collaboration will incorporate Claude, Claude Code and Claude Design across Stifel, with the Dashboard platform serving as a key focus. The system is widely used by Stifel advisors to manage their practices and support client relationships.

Stifel said the goal is to improve the advisor workspace while preserving the familiarity and core functionality of the existing Dashboard platform. The firm plans to combine its knowledge of advisor workflows with Anthropic’s AI capabilities to streamline and enhance the user experience.

The partnership reflects a broader trend among financial institutions toward embedding generative AI directly into advisor and employee workflows rather than deploying it as a standalone tool.

Anthropic said the collaboration is intended to complement human judgment and help advisors deliver greater value to clients, rather than replace the advisory role.

Stifel serves clients from more than 400 offices across the United States and had approximately $577 billion in client assets as of September 30, 2026.

The initiative expands Stifel’s use of AI across wealth management and internal technology, while giving Anthropic another large-scale financial-services deployment for its Claude platform.

💬 🔗

The Investor 11-11-26

Stifel Declares $0.34 Quarterly Common Dividend

Stifel Financial (NYSE: SF) declared a quarterly cash dividend of $0.34 per common share.

The dividend will be paid on December 15, 2026, to shareholders of record as of December 1.

Stifel also declared quarterly dividends on its Series B, Series C and Series D preferred shares. The payments equal approximately $0.390625, $0.3828125 and $0.28125 per depositary share, respectively.

The preferred dividends will also be paid on December 15 to shareholders of record on December 1.

💬 🔗

WS Investor 11-04-26

Stifel Financial Corp. reported record full-year results for 2025, alongside an increased dividend and a stock split, reflecting strong momentum across its core businesses.

For the fourth quarter, Stifel posted net revenues of $1.56 billion, up from $1.36 billion a year earlier, driven mainly by higher investment banking and asset management revenues. Net income available to common shareholders rose to $255.0 million, or $2.31 per diluted share, compared with $2.09 a year ago. On a non-GAAP basis, diluted EPS increased to $2.63.

For the full year 2025, net revenues reached a record $5.53 billion, up from $4.97 billion in 2024. GAAP net income available to common shareholders was $646.5 million, or $5.87 per diluted share, while non-GAAP diluted EPS totaled $6.76. Performance was supported by a 26% increase in investment banking revenue, record asset management revenues up 11%, and record quarter-end client assets of $551.9 billion, up 10% year over year.

The firm also reported strong profitability metrics, including a non-GAAP pre-tax margin of 17.9% for the full year and a return on average tangible common equity of 21.0%, despite elevated legal provisions that weighed on results.

Stifel’s board approved an 11% increase in the common stock dividend beginning in the first quarter of 2026 and declared a three-for-two stock split, effective February 26, 2026. Management described 2025 as a record year for the company and expressed confidence in its ability to navigate market uncertainty while continuing to deliver for clients and shareholders.

💬 🔗

European Investor 01-28-26

Stifel Financial Corp. (NYSE: SF) will release its fourth quarter & full year 2025 financial results before the market opens on Wednesday, January 28, 2026. The company will host a conference call to review the results at 9:30 a.m. Eastern time that same day.

💬 🔗

The Investor 01-25-26

Stifel Financial Corp said that 101 of its wealth management teams have been named to Forbes’ 2026 Best-in-State Wealth Management Teams list. The annual ranking highlights about 6,150 top-performing teams nationwide and is based on research and evaluations conducted by SHOOK Research over a 12-month period ending March 31, 2025.

Stifel said the increased representation reflects the strength of its advisor culture and continued focus on client service. Management noted that recognition from Forbes underscores the firm’s ability to attract and support high-quality wealth management professionals across its national footprint.

💬 🔗

The Investor 01-18-26

Stifel Financial Corp. (NYSE: SF) announced on September 23, 2025, a significant expansion of its Venture Banking team, hiring a group of senior bankers formerly with Silicon Valley Bank to strengthen its presence in life sciences and healthcare. The new hires include Managing Directors Jackie Spencer, Anthony Flores, Milo Bissin, Julie Ebert, Timothy Lew, and Sam Subilia, along with Vice Presidents Tessa Dibble, Lindsey Seidner, and Ariana DaCruz. Collectively, the team brings decades of experience in venture banking, corporate finance, and advisory work across biotech, diagnostics, medical devices, and healthtech.

The move follows strong momentum at Stifel Bank’s Venture & Fund Banking unit, which has grown to more than 100 bankers, surpassed $10 billion in loan commitments, and more than doubled venture client deposits in the past year. Chairman and CEO Ronald J. Kruszewski said the expansion underscores Stifel’s commitment to the innovation ecosystem, particularly in healthcare and life sciences. Jackie Spencer noted that the sectors are at a critical inflection point, with artificial intelligence driving transformative opportunities.

Stifel has recently acted as joint bookrunner on four biopharma financings that raised $1.1 billion, including the first biopharma IPO in seven months. Alongside venture banking, the firm’s healthcare and life sciences work spans equity research, capital raising, M\&A advisory, and industry conferences.

💬 🔗

European Investor 09-24-25

Launny Steffens, a veteran of Merrill Lynch and co-founder of Spring Mountain Capital, will join Stifel as Vice Chairman of Asset Management. In this new role, he will work on expanding Stifel’s financial advisor network, strengthening its asset management business, and sourcing strategic investment banking opportunities.

Steffens spent 38 years at Merrill Lynch, where he led the Private Client Group through major growth, increasing assets under management from $200 billion in 1985 to about $1.6 trillion by 2000. After Merrill, he co-founded Spring Mountain Capital with Greg Ho, focusing on alternative asset investing.

As part of the move, Stifel will acquire over $1 billion in assets under management from Spring Mountain, with key investment professionals staying on. The deal is expected to close later in 2025.

💬 🔗

WS Investor 09-03-25

Stifel Ranks No. 1 in J.D. Power Advisor Satisfaction Study for Third Consecutive Year

Stifel Financial Corp. (NYSE: SF) has once again earned the top spot in the J.D. Power 2025 U.S. Financial Advisor Satisfaction Study, marking its third consecutive year at No. 1. Stifel scored 819 out of 1,000, a 52-point increase from last year and 214 points above the industry average.

The firm also led in five of six individual categories: compensation, leadership and culture, operational support, products and marketing, and technology.

Chairman and CEO Ron Kruszewski called the recognition “a challenge to keep raising the bar,” while President Jim Zemlyak emphasized the firm’s culture of advisor support. Stifel currently employs about 2,340 advisors managing $517 billion in client assets as of June 30, 2025.

💬 🔗

The Investor 07-16-25

Stifel Signs Olympic Champion Kristen Faulkner as Brand Ambassador

Stifel Financial Corp. (NYSE: SF) announced the signing of Olympic gold medalist Kristen Faulkner as its newest brand ambassador. Faulkner made history at the 2024 Paris Olympics by winning gold in both the women’s individual road race and team pursuit in track cycling—becoming the first American woman to win both in a single Games.

Before her athletic success, Faulkner worked in venture capital at Bessemer Venture Partners and Threshold Ventures. Her unique path from finance to Olympic champion exemplifies Stifel’s motto: “Where Success Meets Success.”
In her ambassador role, Faulkner will support initiatives promoting financial wellness, appear in creative campaigns, and engage in community outreach. She joins a lineup of Stifel athletes that includes Mikaela Shiffrin, Jessie Diggins, and Alex Ferreira. Stifel is also a proud partner of the U.S. Ski Team, the St. Louis Cardinals, and other major sports entities.

💬 🔗

WS Investor 06-20-25

Stifel Announces Retirement of Victor Nesi as Co-President and Head of Institutional Group; Joins Board of Directors

ST. LOUIS, June 11, 2025 – Stifel Financial Corp. (NYSE: SF) announced today that Victor Nesi, Co-President and Head of the Institutional Group, will retire from his executive roles effective July 1, 2025, after 16 years of service. Mr. Nesi will continue to contribute to the firm as a member of the Board of Directors.

“Victor has been instrumental in building the platform we have today,” said Ronald J. Kruszewski, Chairman and CEO. “The transformation of our Institutional Group under his guidance is one of the great success stories in our firm’s history.”

Since joining Stifel in 2009, Nesi oversaw the Institutional Group's revenue growth from $391 million to $2.2 billion at its peak, with investment banking revenue increasing 20x to a record $1.6 billion. In 2024, the Institutional Group reported $1.6 billion in revenue, more than four times its 2009 level.

Mr. Nesi’s retirement marks the end of a transformative era, but he leaves behind a seasoned leadership team and solid infrastructure designed for long-term success.

“It has been an honor and privilege to help grow Stifel into a premier full-service investment bank,” said Nesi. “I’m proud of what we’ve built and excited to continue supporting the firm in my new capacity on the Board.”

With a career spanning four decades, Nesi previously held senior roles at Merrill Lynch, Salomon Brothers, and Goldman Sachs, and practiced law at Shea & Gould.

💬 🔗

M

ME NEWS 06-12-25

Load More

NASDAQ:ALVOFollow

Track all markets on TradingView - Prices are not updated in real time

Alvotech Rises 6.7% Premarket as Q3 Product Revenue Jumps and EBITDA More Than Doubles

Alvotech (NASDAQ: ALVO) shares rose about 6.7% in premarket trading after the biosimilar drugmaker reported stronger third-quarter commercial performance, sharply higher adjusted EBITDA and continued manufacturing and pipeline progress.

Third-quarter total revenue was $111.6 million, down 2% year over year, but product and service revenue increased 78.3% to $58.2 million. Adjusted EBITDA more than doubled to $31.5 million from $14.4 million a year earlier.

For the first nine months of 2026, total revenue declined 23% to $323.4 million, while gross margin fell to 54% from 59%. However, adjusted EBITDA increased 15.1% to $78.3 million.

Alvotech highlighted several regulatory and manufacturing milestones. The FDA accepted its application for AVT80, a proposed biosimilar to Entyvio, while Alvotech and Advanz Pharma submitted what they described as the first proposed biosimilar application for high-dose Eylea. The company also secured FDA approvals that expand Simlandi manufacturing capacity in Reykjavik, including a process that more than doubles output per batch.

The company maintained its full-year 2026 guidance for revenue of $650-$700 million and EBITDA of $180-$220 million, although it now expects results toward the lower end of those ranges.

Alvotech ended September with $61.5 million in cash, down from $172.4 million at the end of 2025, leaving execution on fourth-quarter product deliveries particularly important.

The 6.7% premarket gain appears to reflect the strong rebound in product revenue, significant Q3 EBITDA growth and improved manufacturing capacity, despite lower year-to-date revenue and a more cautious position within the existing full-year guidance range.

💬 🔗

European Investor 11-12-26

Load More

NYSE:ENSFollow

Track all markets on TradingView - Prices are not updated in real time

EnerSys Falls 1.6% After Hours as Revenue Miss and Softer Q3 Outlook Offset Strong EPS Growth

EnerSys (NYSE: ENS) shares fell about 1.6% in after-hours trading after the company reported strong earnings growth and margin expansion, but second-quarter revenue came in below guidance and the third-quarter outlook pointed to softer sequential earnings.

Fiscal second-quarter net sales were $949.9 million, essentially flat year over year and below the company’s guidance range of $955-$995 million. EnerSys attributed the shortfall primarily to foreign currency translation.

Profitability remained strong. GAAP diluted EPS rose 34% to $2.42, while adjusted diluted EPS increased 22% to $3.22. Gross margin expanded to 29.9% from 29.1%, and adjusted operating earnings increased to $152.4 million from $133.9 million.

Performance was supported by more than 20% sales growth in Precision Power Solutions and double-digit data-center growth within Network and Infrastructure Solutions. These gains helped offset continued weakness in the material-handling business.

EnerSys also maintained a strong balance sheet, with net leverage at 0.8x EBITDA. The company returned about $140 million to shareholders during the quarter, including $130 million of share repurchases, and generated $143 million of operating cash flow.

For the third quarter, EnerSys expects revenue of $935-$975 million and adjusted EPS of $3.05-$3.15, below the $3.22 delivered in Q2. Management cited tougher margin comparisons and ongoing mix effects, even as demand remains strong in aerospace and defense, data centers and transportation.

The 1.6% after-hours decline appears to reflect the revenue miss and softer sequential EPS outlook, which outweighed strong margin expansion, earnings growth and cash generation.

💬 🔗

European Investor 11-12-26

EnerSys Stock Jumps 11% Premarket as Earnings Surge and Data Center Demand Strengthens

EnerSys (NYSE: ENS) shares jumped 11% in premarket trading Thursday after the energy-storage company reported strong fiscal first-quarter 2027 results, highlighted by sharply higher earnings, margin expansion and continued momentum in data centers, communications and aerospace and defense.

Net sales rose 5% year over year to $936 million, while gross margin expanded 510 basis points to 33.5%. GAAP diluted EPS more than doubled to $3.09, while adjusted EPS surged 64% to $3.66. Even excluding IRC 45X benefits and a one-time tariff refund, adjusted EPS increased 42%, indicating substantial improvement in the underlying business.

The earnings performance appears to be a major driver of the premarket rally. Adjusted EPS of $3.66 came in well above EnerSys' previous guidance range of $2.80-$2.90.

Data Centers Support Growth Outlook

EnerSys said momentum across data centers, communications and aerospace and defense is generating strong sales growth and margin expansion, helping offset continued weakness in material handling.

For the fiscal second quarter, the company expects revenue of $955 million-$995 million and adjusted EPS of $3.15-$3.25. Management also expects continued strength across data centers, communications and aerospace and defense, alongside early signs of recovery in transportation.

Adding to the positive shareholder story, EnerSys raised its quarterly dividend by 10% to $0.2875 per share. The combination of a sizable earnings beat, expanding margins and exposure to growing data-center infrastructure demand appears to be fueling Thursday's 11% premarket gain.

💬 🔗

Global Finance News 08-13-26

EnerSys Rises 4.84% as Record Full-Year Results and Data Center Momentum Impress Investors

EnerSys climbed 4.84% after the industrial stored energy solutions company reported record full-year fiscal 2026 results, beat its own fourth quarter earnings guidance and offered encouraging demand signals heading into fiscal 2027, with its data center and defense businesses emerging as the key growth drivers.

Full-year net sales reached a record $3.75 billion, up 3.7% year over year, driven by a 3% pricing increase, 2% favorable currency translation and 1% from acquisitions, partially offset by a 2% decline in organic volume. Record adjusted diluted EPS excluding IRC 45X tax credits came in at $6.41, up 15%, while total adjusted diluted EPS reached $10.56, up 4%. The company generated $548 million in operating cash flow and returned $409 million to shareholders through buybacks and dividends during the year — more than double the prior year's $192 million.

The fourth quarter was where the positive surprise landed. Adjusted diluted EPS of $3.19 beat the guidance range of $2.95 to $3.05 by a meaningful margin. Net sales of $988 million came in at the low end of guidance but the earnings beat more than compensated. Free cash flow of $131.2 million improved from $105 million a year earlier, and the net leverage ratio tightened further to 1.1x from 1.3x.

CFO Andrea Funk highlighted strength in Data Center, Communications and Aerospace and Defense as the segments driving favorable price and mix, while acknowledging ongoing softness in Motive Power and Transportation — though she noted order trends in those segments improved sequentially during Q4.

Two new products are advancing into customer commissioning — a battery energy storage system for warehouse operators and a lithium data center solution — both of which point to EnerSys expanding its addressable market beyond traditional industrial battery applications into higher-growth end markets.

For Q1 fiscal 2027, the company guided for net sales of $915 million to $955 million and adjusted diluted EPS excluding 45X of $1.61 to $1.71, reflecting typical seasonal patterns. An Investor Day is scheduled for June 11 at the NYSE where management plans to provide further detail on its strategy and technology roadmap.

The 4.84% gain reflects a market responding to a clean earnings beat, a compelling data center growth narrative and a balance sheet that has been significantly strengthened over the past year.

💬 🔗

The Investor 05-21-26

EnerSys Appoints New CEO, Announces Executive Compensation Updates

EnerSys announced the retirement of CEO David M. Shaffer effective May 22, 2025. He is succeeded by Shawn M. O’Connell, who became CEO and a board member on May 23.

O’Connell’s new compensation includes:
• Annual base salary of $950,000
• Annual incentive target of 115% of salary
• Enhanced severance terms including two years' compensation and COBRA coverage

Shaffer entered into a retirement agreement granting continued vesting of equity awards, pro rata incentive payments, and transfer of his company vehicle, in exchange for restrictive covenants.
Additionally, CFO Andrea J. Funk received a $1.5 million equity award, vesting over four years, to support performance alignment and retention.

💬 🔗

WS News 05-24-25

**EnerSys announces leadership change in technology division**

On March 26, 2025, EnerSys reported the departure of Joern Tinnemeyer from his role as Senior Vice President and Chief Technology Officer. The company did not disclose the reasons for his departure.

Simultaneously, EnerSys appointed Mark Matthews, the company’s President of Specialty Global, as Acting Chief Technology Officer. Matthews will assume this role in addition to his current responsibilities.

The announcement was made through a Form 8-K filing with the SEC and emphasized that the leadership transition is not expected to affect the company’s operations or disclosures under the Exchange Act.

💬 🔗

The Investor 03-29-25

Oppenheimer upgrades ENS from hold to outperform

💬 🔗

European Investor 01-19-25

Load More

NYSE:JPMFollow

Track all markets on TradingView - Prices are not updated in real time

JPMorgan Rises 0.4% After Q3 Earnings Show Strong Markets, Banking and Asset Management Growth

JPMorgan Chase (NYSE: JPM) shares rose about 0.4% after the bank reported third-quarter 2026 net income of $15.3 billion, or $5.57 per share. Excluding a significant investment securities loss, net income was $15.8 billion, or $5.75 per share.

Reported revenue reached $50.2 billion, while managed revenue was $50.9 billion. Return on equity was 17% and return on tangible common equity was 20%, rising to 21% excluding the significant item.

The Corporate & Investment Bank was a major growth driver. Investment banking fees increased 14% year over year, while Markets revenue rose 15%. Equity Markets was particularly strong, surging 49%, more than offsetting a 4% decline in Fixed Income Markets.

Consumer & Community Banking also remained resilient, with revenue rising 9%. Debit and credit card sales volume increased 10% year over year, active mobile customers grew 7%, and JPMorgan added more than 650,000 net new checking accounts during the quarter. The Card Services net charge-off rate was 2.91%.

Asset & Wealth Management delivered another strong quarter, with revenue up 14% and assets under management reaching $5.2 trillion, 13% higher than a year earlier. The division recorded $263 billion of client asset net inflows, while average loans increased 20%.

Credit costs totaled $2.7 billion, including $2.2 billion of net charge-offs and a $539 million reserve build. Firmwide average loans increased 10% year over year, while average deposits rose 8%.

The bank also reported a $658 million net investment securities loss in Corporate, reducing EPS by $0.18. JPMorgan returned capital through a $4.4 billion common dividend and $664 million of net share repurchases, though CEO Jamie Dimon said the company reduced buybacks during the quarter to preserve capital for potentially attractive deployment opportunities.

The modest gain in JPMorgan shares appears to reflect another strong operating quarter, particularly in equities, investment banking and asset management, balanced against higher credit costs, lower repurchases and Dimon’s continued caution around sticky inflation, elevated asset prices, rising rates and geopolitical risks.

💬 🔗

European Investor 10-13-26

Ford, JPMorganChase and Michigan Launch $2 Billion Industrial Growth Initiative

Ford Motor Company, JPMorganChase, the State of Michigan, Michigan Central and Newlab have launched Michigan LIFT, a public-private initiative designed to accelerate manufacturing innovation, strengthen domestic supply chains and help emerging suppliers scale production.

Ford plans to serve as the anchor industrial buyer and aspires to award up to $1 billion in contracts to participating suppliers over the next decade. JPMorganChase, meanwhile, aims to provide up to $1 billion in debt financing through the platform as part of its broader Security and Resiliency Initiative. :chatgpt-content-reference{index="0"}

Michigan LIFT will match manufacturing and supply-chain challenges identified by industrial buyers with suppliers capable of addressing them. Companies that advance through the program may receive support involving customer demand, financing, state resources, workforce development and commercialization services.

Initial focus areas include robotics and advanced manufacturing automation, semiconductors, batteries and advanced energy, aerospace and mobility, critical minerals and life sciences manufacturing.

Michigan Central will provide testing and scaling infrastructure, while Newlab plans to contribute $20 million in in-kind support. The partners also aim to attract 10 to 20 additional industrial buyers representing more than $1 billion in annual demand by 2036.

The initiative is designed to address a common problem for industrial startups and suppliers: promising technologies often struggle to reach commercial scale because customer demand, financing, workforce availability and qualification processes are not aligned. Michigan LIFT seeks to bring those pieces together within a single manufacturing ecosystem.

💬 🔗

WS Investor 09-29-26

Microsoft Corp. on Tuesday announced that its board of directors declared a quarterly dividend of $0.98 per share, reflecting a 7 cent or 8% increase over the previous quarter’s dividend. The dividend is payable Dec. 10, 2026, to shareholders of record on Nov. 19, 2026. The ex-dividend date will be Nov. 19, 2026.

The Board of Directors of JPMorgan Chase & Co. (NYSE: JPM) declared a quarterly dividend of $1.65 per share on the outstanding shares of the common stock of JPMorganChase, an increase from the prior quarterly dividend of $1.50 per share. The dividend is payable on October 31, 2026, to stockholders of record at the close of business on October 6, 2026.

💬 🔗

WS Investor 09-16-26

JPMorgan (JPM) Stock Rises as Strong Investment Banking and Trading Drive Record Second-Quarter Results

JPMorgan Chase (NYSE: JPM) shares gained 1.2% on Tuesday after the banking giant reported better-than-expected second-quarter results, supported by record revenue across its businesses and exceptionally strong performance in investment banking and trading.

The bank posted reported net income of $21.2 billion, or $7.70 per share, including significant gains from Visa shares and certain equity investments. Excluding those items, net income totaled $16.9 billion, or $6.14 per share. Reported revenue reached $57.3 billion, while managed revenue came in at a record $58.0 billion.

Performance was strong across all major business segments. Investment banking fees surged 30% year over year to their highest level since 2021, driven by increased deal activity and capital markets issuance. Markets revenue jumped 35%, with equity trading soaring 86% amid elevated client activity and strong financing demand, while fixed-income trading rose 6%.

The consumer business also remained resilient. Average loans increased 10% from a year earlier, deposits rose 7%, and debit and credit card spending climbed 10%. Meanwhile, assets under management reached a record $5.1 trillion, up 18% year over year, supported by $50 billion in long-term net inflows.

Chairman and CEO Jamie Dimon said the U.S. economy has remained resilient thanks to stronger business investment, AI-driven capital spending, fiscal stimulus, and regulatory improvements. However, he also warned that geopolitical conflicts, persistent inflation, large fiscal deficits, and elevated asset valuations continue to pose meaningful risks to the economic outlook.

The results reinforced JPMorgan's position as one of the strongest-performing global banks, with investors responding positively to robust capital markets activity, healthy consumer trends, and continued growth across its diversified businesses. Investors will continue watching management's outlook for investment banking activity, credit quality, and the broader macroeconomic environment in the second half of the year.

💬 🔗

The Investor 07-14-26

JPMorgan Falls Despite Truist Price Target Increase

JPMorgan Chase (NYSE: JPM) shares fell 1.8% on Friday even as Truist Financial raised its price target on the banking giant to *$344 from $332*, while maintaining a *Hold* rating.

The higher price target reflects Truist's improved outlook for JPMorgan's earnings potential and the bank's continued strength across its diversified businesses. While the firm acknowledged JPMorgan's solid fundamentals and industry-leading franchise, it kept its neutral rating, suggesting much of the upside may already be reflected in the stock's valuation.

Despite the positive target revision, JPMorgan ended Friday lower as selling pressure weighed on the broader financial sector. Nevertheless, the increased price target signals that analysts remain constructive on the bank's long-term outlook and earnings resilience.

💬 🔗

The Investor 06-27-26

JPMorgan Chase & Co. declared dividends on its Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series CC.

The bank announced a dividend of $159.02 per preferred share, equivalent to $15.9020 per depositary share. The payment will be made on May 1, 2026, to shareholders of record as of April 1, 2026.

Dividends for the Series CC preferred stock have been calculated under the floating-rate period that began on November 1, 2022.

💬 🔗

European Investor 03-14-26

Apple announced that JPMorgan Chase will become the new issuer of Apple Card, replacing the current issuing bank, with the transition expected to take place over approximately 24 months.

Apple said Apple Card users will continue to receive the same benefits during and after the transition, including up to 3% unlimited Daily Cash back, integrated spending and budgeting tools in Apple Wallet, Apple Card Family features, and access to a high-yield savings account. Mastercard will remain the payment network, ensuring continued global acceptance and existing card benefits.

The companies said the partnership reflects a shared focus on innovation, customer experience, and consumer financial health. Apple emphasized that there will be no immediate changes for users, who can continue using their Apple Card as usual while additional details will be communicated closer to the transition date.

💬 🔗

WS Investor 01-08-26

JP Morgan 3Q results

💬 🔗

WS News 10-14-25

Earnings season is here …

💬 🔗

WS News 10-12-25

JPMorgan Chase Closes $4 Billion Subordinated Notes Offering

JPMorgan Chase & Co. announced the successful closing of a $4 billion public offering of Fixed-to-Floating Rate Subordinated Notes due 2036.

The offering was made under an existing shelf registration and includes legal opinions filed as part of the company’s SEC Form 8-K submission. The notes will support the bank’s capital and funding strategy.

💬 🔗

The Investor 07-24-25

Load More

11-11-26The Investor

10-13-26The Investor

09-30-26WS News

09-29-26WS News

NASDAQ:EZPWFollow

Track all markets on TradingView - Prices are not updated in real time

EZCORP Jumps 11% After Hours as Record Revenue and Pawn Loan Growth Drive Strong Q4

EZCORP (NASDAQ: EZPW) shares surged about 11% in after-hours trading after the pawn lender reported record fourth-quarter revenue, strong earnings growth and continued expansion across its core pawn business.

Fourth-quarter revenue increased 33% year over year to $447.1 million, while gross profit rose 29% to $255.8 million. Core pawn revenue climbed 27% to $383.4 million and core pawn gross profit increased 29% to $243.6 million.

Net income attributable to EZCORP rose 28% to $34.3 million, while adjusted net income increased 27% to $34.1 million. Diluted EPS climbed 26% to $0.43, and adjusted EBITDA increased 33% to $64.0 million.

Pawn loans outstanding reached $402.8 million, up 31% year over year. Same-store pawn loan balances increased 13% in the U.S. and 25% in Latin America, reflecting strong customer demand and continued lending growth.

For fiscal 2026, total revenue rose 33% to $1.69 billion and adjusted EBITDA increased 47% to $276.7 million. Full-year diluted EPS jumped 46% to $2.07.

EZCORP also significantly expanded its footprint, adding a net 230 stores during the year through acquisitions and new openings, bringing its total network to 1,590 locations across 15 countries. The company completed its acquisition of the remaining interest in SMG during the fourth quarter.

The 11% after-hours rally appears to reflect broad-based strength across revenue, earnings, pawn loan growth and store expansion, along with management’s confidence that the operating momentum can continue into fiscal 2027.

💬 🔗

European Investor 11-12-26

Load More

NYSE:LLYFollow

Track all markets on TradingView - Prices are not updated in real time

Lilly Reports Strong One-Year Results for Taltz and Zepbound Combination in Psoriatic Arthritis

Eli Lilly (NYSE: LLY) reported positive 52-week Phase 3b data showing that Taltz and Zepbound used together produced stronger and more durable outcomes than Taltz alone in adults with active psoriatic arthritis and obesity or overweight.

At one year, 43.7% of patients receiving the combination achieved ACR50, indicating at least a 50% improvement in psoriatic arthritis disease activity, compared with 15.7% of patients receiving Taltz alone. Lilly said the difference was already visible by Week 4, before clinically meaningful weight loss had occurred.

The combination also produced substantially stronger weight-loss outcomes. At Week 52, 85.7% of patients receiving Taltz plus Zepbound achieved at least 10% weight reduction, compared with 6.7% on Taltz alone. Meanwhile, 39.2% of combination-treated patients achieved both ACR50 and at least 10% weight loss versus 1.7% with Taltz monotherapy.

Additional measures also favored the combination, including minimal disease activity, physical function, fatigue and inflammatory markers. Lilly reported improvements in metabolic measures including BMI, body weight, systolic blood pressure, glucose, HbA1c, triglycerides and total cholesterol.

Safety findings were generally consistent with the established profiles of both medicines, with most adverse events described as mild to moderate.

The results strengthen Lilly’s broader immunometabolic strategy by suggesting that simultaneously targeting inflammatory disease and obesity may provide greater clinical benefit than treating psoriatic arthritis alone in patients affected by both conditions.

💬 🔗

The Investor 11-11-26

Lilly’s Foundayo Cuts Sleep Apnea Severity in Phase 3, Supporting FDA Filing

Eli Lilly (NYSE: LLY) reported positive Phase 3 results for Foundayo, or orforglipron, showing significant reductions in obstructive sleep apnea severity in adults with obesity or overweight, with and without positive airway pressure therapy.

At 52 weeks, Foundayo reduced the apnea-hypopnea index by 43.8% in patients not using PAP therapy and by 27.5% in those using PAP. Among patients not using PAP, 31.5% achieved remission or mild disease, while 19.6% of PAP users reached that threshold.

The drug also reduced sleep apnea-specific hypoxic burden by 55.9% in patients not using PAP and by 45.8% in those using PAP, suggesting meaningful improvement in overnight oxygen-related stress. Participants also lost about 11% of body weight on average and showed reductions in systolic blood pressure and inflammation.

The overall safety profile was consistent with earlier Foundayo studies, with gastrointestinal side effects including nausea, diarrhea, constipation and vomiting among the most common adverse events.

Lilly plans to submit Foundayo to the FDA for moderate-to-severe obstructive sleep apnea by the end of 2026. Foundayo is already approved in the U.S. for obesity, giving Lilly a potential pathway to broaden the drug’s commercial use into another major obesity-related condition.

The Phase 3 data strengthen Lilly’s cardiometabolic franchise by showing that oral GLP-1 therapy may deliver benefits beyond weight loss, including clinically meaningful improvements in sleep apnea and associated cardiovascular risk factors.

💬 🔗

The Investor 11-09-26

Eli Lilly and Hims & Hers Partner to Expand Access to Zepbound and Foundayo

Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) announced an agreement to make Lilly’s FDA-approved obesity medicines Zepbound and Foundayo available through the Hims & Hers platform.

Eligible patients will be able to complete a telehealth consultation, receive a prescription when appropriate and have the medicines shipped directly to their homes without leaving the platform. Self-pay pricing will start at $149 per month for Foundayo and $299 per month for Zepbound.

The partnership gives Lilly another direct channel to reach obesity patients through digital healthcare while allowing Hims & Hers to expand its weight-loss offering with branded, FDA-approved GLP-1 medicines.

Hims & Hers said it has never offered compounded copies of Lilly’s GLP-1 products and committed not to do so in the future. The companies also said prescribing decisions will remain with independent licensed providers.

The agreement could strengthen Lilly’s reach in the rapidly growing obesity market while giving Hims & Hers a more competitive position in telehealth weight management through access to two of Lilly’s major obesity products.

💬 🔗

Global Finance News 11-07-26

Eli Lilly Breaks Ground on $5 Billion Virginia Plant to Expand U.S. Cancer Drug Manufacturing

Eli Lilly (NYSE: LLY) broke ground on a new $5 billion manufacturing facility in Goochland County near Richmond, Virginia, expanding its U.S. production footprint for next-generation cancer medicines.

The Richmond site will be Lilly’s first fully integrated facility capable of producing both active pharmaceutical ingredients and finished medicines. It will include dedicated API capacity for bioconjugates and large-molecule therapies, including antibody-drug conjugates, or ADCs.

Lilly said the facility will support production of targeted cancer treatments designed to combine antibodies with potent cytotoxic medicines, allowing therapies to attack diseased cells more selectively while limiting exposure to healthy tissue. The company is also exploring ADC technology in autoimmune diseases and other indications.

The project is part of Lilly’s more than $50 billion U.S. manufacturing expansion and represents one of 10 new domestic sites announced since 2020. Five of those facilities are focused on API production.

The Richmond plant is expected to create about 650 high-wage permanent jobs across engineering, science, operations and laboratory functions, along with roughly 1,800 construction jobs. Lilly has also committed $40 million to support the Virginia Center for Advanced Pharmaceutical Manufacturing, including a hands-on training center targeted to open in 2028.

The facility will use machine learning, AI, digitally integrated systems and advanced analytics to support manufacturing efficiency and quality control. Lilly is also targeting LEED Gold certification for the site.

The investment strengthens Lilly’s U.S. manufacturing capacity at a time when the company is expanding across oncology, obesity, immunology and other high-growth therapeutic areas. The Richmond facility adds domestic capacity for more complex biologic medicines and could improve supply-chain resilience as Lilly scales its next generation of cancer treatments.

💬 🔗

WS Investor 10-22-26

Lilly Says Oral GLP-1 Foundayo Reduced Predicted Diabetes and Cardiovascular Risk in ATTAIN-1 Analysis

Eli Lilly said post-hoc analyses of its Phase 3 ATTAIN-1 trial found that Foundayo, or orforglipron, was associated with meaningful reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight.

At 72 weeks, the highest 17.2 mg dose was associated with an estimated 57% reduction in predicted 10-year type 2 diabetes risk versus placebo and an 18% reduction in predicted cardiovascular disease risk. The 5.5 mg and 9 mg doses were associated with estimated diabetes-risk reductions of 45% and 50%, respectively.

The analysis used established risk models rather than measuring actual future cardiovascular events or diabetes diagnoses, so the findings reflect predicted risk rather than observed clinical outcomes.

Foundayo is a once-daily oral GLP-1 receptor agonist and is already approved in the U.S. for chronic weight management in adults with obesity or certain adults with overweight and related medical conditions. Unlike peptide-based GLP-1 treatments, it is a small-molecule oral drug that can be taken without food or water restrictions.

Lilly said the results add to evidence that weight-loss therapies may provide benefits beyond body-weight reduction by improving several cardiometabolic risk factors, including blood glucose, blood pressure and cholesterol.

💬 🔗

WS Investor 10-01-26

Eli Lilly’s EloraTZP Delivers Greater Weight Loss Than Tirzepatide in Phase 2b Study

Eli Lilly reported positive Phase 2b results for EloraTZP, an investigational combination of eloralintide and tirzepatide, in adults with obesity or overweight and type 2 diabetes.

At 48 weeks, participants receiving the highest-dose EloraTZP regimen lost an average of 54.1 pounds, or 23.3% of body weight, compared with 34.4 pounds, or 14.8%, for tirzepatide 15 mg alone. The combination also reduced A1C by up to 2.9 percentage points versus 2.4 points with tirzepatide.

EloraTZP combines eloralintide, a selective amylin receptor agonist, with tirzepatide, which targets GIP and GLP-1 receptors. Lilly is aiming to simultaneously engage three metabolic pathways involved in appetite and glucose regulation.

The study enrolled 367 adults and met its primary and secondary endpoints. The most common adverse events were gastrointestinal and were generally mild or moderate, although discontinuation rates due to adverse events were higher in some EloraTZP combination groups.

Lilly said it plans to begin Phase 3 trials of a co-formulated EloraTZP product in the fourth quarter of 2026.

The results strengthen Lilly’s obesity and diabetes pipeline by suggesting that adding an amylin-based mechanism to tirzepatide could deliver additional weight loss and glucose control beyond tirzepatide alone.

💬 🔗

The Investor 09-30-26

Eli Lilly Highlights Strong Retatrutide Weight-Loss Data Ahead of EASD 2026

Eli Lilly (NYSE: LLY) will present new clinical data across its obesity and diabetes portfolio at the EASD 2026 meeting, with updates covering retatrutide, Foundayo, Mounjaro and the experimental eloraTZP combination.

Among the most notable results, Lilly’s Phase 3 TRIUMPH-2 trial showed that adults with obesity or overweight and type 2 diabetes taking retatrutide lost up to an average of 49.6 pounds, or 20.8% of body weight, over 80 weeks. A1C levels declined by as much as an average of 1.6 percentage points. Retatrutide is a once-weekly drug targeting GIP, GLP-1 and glucagon receptors.

Lilly will also unveil Phase 2 results for eloraTZP, which combines eloralintide with tirzepatide. Earlier Phase 1 data showed 17% weight loss over 16 weeks with the combination, compared with 10% for tirzepatide alone. Meanwhile, Foundayo data showed potentially favorable cardiovascular signals in patients with type 2 diabetes.

The results highlight Lilly’s strategy to build a broader next-generation obesity franchise beyond Zepbound and Mounjaro, with oral, triple-agonist and combination therapies targeting different segments of the rapidly expanding cardiometabolic market.

💬 🔗

The Investor 09-15-26

Eli Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Drug Pipeline

Eli Lilly has completed its acquisition of AtaiBeckley, strengthening the pharmaceutical company’s neuroscience pipeline with experimental therapies targeting treatment-resistant depression and other mental health conditions.

AtaiBeckley is a clinical-stage biotechnology company developing rapid-acting neuroplastogens. Its lead investigational program, BPL-003, is being developed for treatment-resistant depression, a condition in which patients continue to experience symptoms despite multiple treatment attempts.

The acquisition gives Lilly access to a pipeline designed around rapid-acting therapies that could potentially reduce reliance on chronic dosing. Lilly said it plans to advance AtaiBeckley’s programs as part of its broader neuroscience strategy.

The transaction was completed after receiving approval from AtaiBeckley shareholders at a special meeting. Financial terms were not disclosed in the announcement.

The deal further expands Lilly beyond its major diabetes and obesity franchises as the company invests across neuroscience, oncology and immunology, with AtaiBeckley adding a new approach to its mental health drug development portfolio.

💬 🔗

The Investor 09-11-26

Eli Lilly Reports Strong One-Year Results for Taltz and Zepbound Combination

Eli Lilly (NYSE: LLY) announced positive 52-week Phase 3b data Monday showing that Taltz and Zepbound used together produced durable improvements in adults with psoriatic disease and obesity.

The results come from the TOGETHER-PsO and TOGETHER-PsA trials, which compared Taltz plus Zepbound with Taltz alone. The combination had already demonstrated statistically superior results at the Week 36 primary endpoint, and Lilly said those improvements were maintained or further strengthened through Week 52.

In the psoriasis trial, 30.6% of patients receiving the combination achieved both complete skin clearance and at least 10% weight loss, compared with 4.4% receiving Taltz alone. Complete skin clearance was achieved by 40.5% of combination-treated patients versus 29.1% with Taltz alone.

Results were also strong in psoriatic arthritis. About 39.2% of patients receiving both drugs achieved at least a 50% improvement in disease activity together with at least 10% weight loss, compared with just 1.7% in the Taltz-only group. The proportion achieving a 50% improvement in disease activity reached 43.7% versus 15.7% with monotherapy.

The combination also produced sustained or improved results across measures including systemic inflammation, BMI, blood pressure, glucose, HbA1c, triglycerides and cholesterol. No new safety concerns were identified, with adverse events generally mild to moderate and consistent with the known profiles of the two medicines.

The findings are significant for Lilly because they suggest Zepbound's role could extend beyond weight management when used alongside established therapies for diseases closely associated with obesity. The data could strengthen the company's position across both the rapidly growing obesity market and immunology, while supporting a broader strategy of treating interconnected metabolic and inflammatory diseases.

💬 🔗

The Investor 08-31-26

FDA Approves Lilly’s Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes

Eli Lilly (NYSE: LLY) received U.S. FDA approval for Mounjaro (tirzepatide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk, significantly expanding the drug’s clinical profile beyond blood-sugar control.

The new indication covers cardiovascular death, non-fatal heart attack and non-fatal stroke. Lilly said Mounjaro is now the first and only GIP/GLP-1 receptor agonist proven to lower these cardiovascular risks in high-risk adults with type 2 diabetes, alongside its established A1C and weight-loss benefits.

Approval was based on the large SURPASS-CVOT Phase 3 trial involving more than 13,000 patients. Mounjaro demonstrated non-inferiority to Lilly’s Trulicity, an established GLP-1 therapy with cardiovascular benefits, and recorded an 8% lower rate of cardiovascular death, heart attack or stroke. However, statistical superiority over Trulicity was not established.

The approval is commercially important for Lilly because it strengthens Mounjaro’s competitive position in the rapidly expanding incretin market. Cardiovascular benefits have become an increasingly important differentiator for GLP-1-based medicines, and the broader label could support greater adoption of Mounjaro among high-risk diabetes patients.

💬 🔗

European Investor 08-28-26

Load More

09-28-26WS News

09-15-26The Investor

09-15-26The Investor

07-13-26European Investor

06-26-26Global Finance News